Bayer Taiwan Co., Ltd.
|Title of Study||
OPTIMIS - Outcomes of HCC patients treated with TACE followed or not followed by sorafenib and the
influence of timing to initiate sorafenib
The primary objective of this study is the comparison of two cohorts of hepatocellular carcinoma patients regarding overall survival (OS) from time of TACE noneligibility.
The two cohorts of special interest are defined based on the investigators’ treatment decisions
(i.e. patients with early start of Sorafenib treatment vs. patients without early start of Sorafenib treatment).
|Number of Sites||
|Period of Study||
|Number of Patients||
|IRB Approval Date||
|Publication Plan / Date||